Therapeutic Potential of Mesenchymal Stem Cells in Immune-Mediated Diseases

被引:15
|
作者
Eljarrah, Adam [1 ,2 ]
Gergues, Marina [1 ,2 ]
Pobiarzyn, Piotr W. [1 ,2 ]
Sandiford, Oleta A. [1 ,2 ]
Rameshwar, Pranela [3 ]
机构
[1] Rutgers New Jersey Med Sch, Dept Med, Newark, NJ USA
[2] Univ Med & Dent New Jersey, Grad Sch, Rutgers Sch, Newark, NJ USA
[3] Rutgers Sch Biomed Hlth Sci, New Jersey Med Sch, Dept Med, Div Hematol Oncol, Newark, NJ 07107 USA
来源
关键词
Mesenchymal stem cells; Cytokines; Cell therapy; Drug delivery; Immune response; Graft-versus-host response; REGULATORY T-CELLS; MARROW STROMAL CELLS; VERSUS-HOST-DISEASE; B-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; DENDRITIC CELLS; MURINE MODEL; INHIBIT; PROLIFERATION; DIFFERENTIATION;
D O I
10.1007/978-3-030-31206-0_5
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Mesenchymal stem cells (MSCs) are multipotent cells that can self--renew and differentiate into cells of all germ layers. MSCs can be easily attracted to the site of tissue insult with high levels of inflammatory mediators. The general ability of MSCs to migrate at the sites of tissue injury suggested an innate ability for these cells to be involved in baseline tissue repair. The bone marrow is one of the primary sources of MSCs, though they can be ubiquitous. An attractive property of MSCs for clinical application is their ability to cross allogeneic barrier. However, alone, MSCs are not immune suppressive cells. Rather, they can be licensed by the tissue microenvironment to become immune suppressor cells. Immune suppressor functions of MSCs include those that blunt cytotoxicity of natural killer cells, suppression of T-cell proliferation, and "veto" function. MSCs, as third-party cells, suppress the immune response that generally recapitulates graft-versus-host disease (GvHD) responses. Based on the plastic functions of MSCs, these cells have dominated the field of cell-based therapies, such as anti-inflammatory and drug delivery. Here, we focus on the potential use of MSC for immunological disorders such as Crohn's disease and GvHD.
引用
收藏
页码:93 / 108
页数:16
相关论文
共 50 条
  • [21] Advancement in therapeutic strategies for immune-mediated oral diseases
    Patil, Shankargouda
    Mustaq, Shazia
    Hosmani, Jagadish
    Khan, Zafar Ali
    Yadalam, Pradeep Kumar
    Ahmed, Zeeshan Heera
    Bhandi, Shilpa
    Awan, Kamran Habib
    DM DISEASE-A-MONTH, 2023, 69 (01):
  • [22] Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases
    Wallace, Zachary S.
    Sparks, Jeffrey A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (23): : 2370 - 2372
  • [23] Immune-Mediated Skin Diseases: Future Therapeutic Perspectives
    Alaibac, Mauro
    MEDICINA-LITHUANIA, 2023, 59 (10):
  • [24] The microbiota and immune-mediated diseases: Opportunities for therapeutic intervention
    Fitzgibbon, Gillian
    Mills, Kingston H. G.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2020, 50 (03) : 326 - 337
  • [25] Potential therapeutic applications of mesenchymal stem cells for the treatment of eye diseases
    Mannino, Giuliana
    Russo, Cristina
    Longo, Anna
    Anfuso, Carmelina Daniela
    Lupo, Gabriella
    Lo Furno, Debora
    Giuffrida, Rosario
    Giurdanella, Giovanni
    WORLD JOURNAL OF STEM CELLS, 2021, 13 (06): : 632 - 644
  • [26] Generation of CCR5-ablated Human Induced Pluripotent Stem Cells as a Therapeutic Approach for Immune-mediated Diseases
    Rouzbahani, Negin Hosseini
    Kaviani, Saeid
    Vasei, Mohammad
    Soleimani, Masoud
    Azadmanesh, Kayhan
    Nicknam, Mohammad Hossein
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2019, 18 (03) : 310 - 319
  • [27] The therapeutic potential of mesenchymal stem cells
    Picinich, Sonia C.
    Mishra, Pravin J.
    Mishra, Prasun J.
    Glod, John
    Banerjee, Debabrata
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (07) : 965 - 973
  • [28] Potential role of diacylglycerol kinases in immune-mediated diseases
    Baldanzi, Gianluca
    Ragnoli, Beatrice
    Malerba, I. Mario
    CLINICAL SCIENCE, 2020, 134 (13) : 1637 - 1658
  • [29] Pathogenic helper T cells as the novel therapeutic targets for immune-mediated intractable diseases
    Onodera, Atsushi
    Kokubo, Kota
    Okano, Mikiko
    Onoue, Miki
    Kiuchi, Masahiro
    Iwamura, Chiaki
    Iinuma, Tomohisa
    Kimura, Motoko Y.
    Ebihara, Nobuyuki
    Hanazawa, Toyoyuki
    Nakayama, Toshinori
    Hirahara, Kiyoshi
    PHARMACOLOGY & THERAPEUTICS, 2023, 247
  • [30] The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases
    Roncarolo, Maria Grazia
    Gregori, Silvia
    Bacchetta, Rosa
    Battaglia, Manuela
    Gagliani, Nicola
    IMMUNITY, 2018, 49 (06) : 1004 - 1019